Background
==========

*Staphylococcus aureus*(*S. aureus*) is a common human commensal organism and a clinically important invasive pathogen. Methicillin resistant *S. aureus*(MRSA) remains one of the most prevalent pathogens isolated from hospital patients. However, MRSA infections are increasingly arising outside of healthcare settings among individuals in the community with no established risk factors. Furthermore, the incidence of invasive community acquired MRSA (CAMRSA) disease in previously-healthy children has been increasing \[[@B1]-[@B3]\].

CAMRSA strains as defined by the Centers for Disease Control and Prevention (CDC) clinical criteria \[[@B4]\] have some general characteristics that differentiate them from healthcare associated MRSA (HAMRSA) strains, including the presence of the Staphylococcal chromosomal cassette - SCC*mec*type IVa that confers methicillin resistance, *lukSF-PV*genes that codes for Panton-Valentine leukocidin (PVL), arginine catabolic mobile element (ACME) element that contributes to skin colonization \[[@B5]\], antibiotic resistance patterns \[[@B3]\], and pulsed field types (PFT) \[[@B6]\]. Several reports now show the migration of these CAMRSA strains into the hospital setting \[[@B7]-[@B9]\]. A six-fold increase in the number of MRSA infections among children between 2002 and 2007 (p \< 0.0001) (Figure [1](#F1){ref-type="fig"}) prompted us to examine both the clinical profile of the patients, and the molecular profile of the infecting strains at Mercy Children\'s Hospital Toledo, Ohio. We also compared two strain typing methods - pulsed field typing (PFT) and the automated rapid typing method using repetitive sequence-based PCR, the DiversiLab system \[[@B10]\].

![**Comparison of Pediatric MRSA Incidence in two time periods five years apart: June 1st to Dec 31st 2002 and 2007 (p \< 0.0001)**.](1471-2431-11-96-1){#F1}

Methods
=======

MRSA isolate collection and patient medical record review
---------------------------------------------------------

This is a retrospective, descriptive, single-cohort study conducted at Mercy Children\'s Hospital, Toledo, Ohio and was approved by the institutional review board. Pediatric patients (\< 18 yrs of age), who were culture positive for MRSA between June 1 to December 31, 2007, were identified by the clinical microbiology laboratory (Mercy Integrated Laboratories, Toledo, Ohio). This facility also provided us with a sample of the clinical isolate that had been frozen at -80°C in a solution of 50% brain-heart infusion and 50% glycerol for later analysis.

Medical charts of these patients were reviewed for social and demographic information including age, gender, race, socio-economic status based on insurance, pre-existing history of skin and soft tissue infection (SSTI); respiratory, cardiovascular, gastrointestinal, and nervous system diseases, type of care (outpatient *vs*. emergency room *vs*. inpatient care) and site of infection. Antimicrobial susceptibilities were determined based on Clinical and laboratory Standard Institute (CLSI) guidelines at the clinical laboratory using the Vitek system for oxacillin, erythromycin, clindamycin, vancomycin, ciprofloxacin, tetracycline, trimethoprim/sulfamethoxasole, rifampin and linezolid. All erythromycin-resistant strains were tested for inducible clindamycin resistance using the D-test \[[@B11]\] before final susceptibilities were reported.

Strain Typing
-------------

*Pulsed Field typing (PFT)*: Strain typing was done by PFT as described by Chang *et al*\[[@B12]\], using *Sma*I as the restriction enzyme, at the Children\'s Memorial Hospital, Chicago, Illinois. The relatedness of isolates was based on visual comparison of band patterns by the use of criteria described by Tenover *et al*\[[@B13]\].

*DiversiLab*typing: Strain typing was also performed using the DiversiLab System at Mercy Integrated Laboratories. This is an automated method using repetitive sequence-based PCR that targets multiple noncoding repetitive sequences in the genomic DNA. Band patterns were subsequently analyzed using the web-based DiversiLab software \[[@B10]\].

DNA Extraction and PCR
----------------------

Clinical isolates were grown on 5% blood agar plates overnight at 37°C. DNA was extracted from the isolates using the Wizard^®^Genomic DNA Purification Kit. PCR amplification was then performed on all patient isolates for the presence of *mecA*, SCC*mec*typing, *arcA*, ACME, *lukSF-PV*and *cap5*genes (Additional file [1](#S1){ref-type="supplementary-material"}) \[[@B14]-[@B17]\].

Statistical Analysis
--------------------

Fisher\'s Exact test was used to explore for associations of site of infection, pre-existing SSTI and respiratory disease with age group and PFGE type. A Fisher\'s Exact p-value of \< 0.05 was considered statistically significant. Data were analyzed using SAS (SAS Cary, NC, version 9).

Results
=======

From June 1, 2007 to December 31, 2007, 63 pediatric patients with MRSA infections were seen at the emergency room, outpatient clinics and the inpatient ward at Mercy Children\'s Hospital. Of these, only 5 patients did not meet the CDC clinical criteria for CAMRSA \[[@B4]\]. Thus, 58 (92%) of all pediatric MRSA infections were community-acquired. All of these CAMRSA infections were SSTIs. During this time period there were no other culture positive invasive pediatric MRSA infections like bacteremia, sepsis, endocarditis, pneumonia, or osteomyelitis.

The patient characteristics for CAMRSA infections are shown in Table [1](#T1){ref-type="table"}. The turnover of patients at Mercy Children\'s Hospital in 2007 was about 22,000 (inpatients 2400) pediatric patients. In 2007, 26% of all children seen at Mercy Children\'s hospital were African American compared to 62% of our CAMRSA patients and; 51% were Medicaid insurance patients and therefore belonged to the lower socio economic group compared to 74% of our CAMRSA patients. All of these CAMRSA isolates were susceptible to trimethoprim/sulfamethoxasole, clindamycin, rifampin, linezolid and vancomycin.

###### 

Patient Characteristics

                                                             n (%)
  ---------------------------------------------------------- ----------
  Age group (years)                                          
   0-3                                                       25 (43%)
   4-12                                                      19 (33%)
   13-18                                                     14 (24%)
                                                             
  Gender                                                     
   Female                                                    36 (62%)
   Male                                                      22 (38%)
                                                             
  Race                                                       
   Caucasian                                                 16 (29%)
   African American                                          34 (62%)
   Other                                                     5 (9%)
                                                             
  Type of Visit                                              
   ER                                                        27 (47%)
   Inpatient                                                 11 (19%)
   Outpatient                                                20 (34%)
                                                             
  Insurance                                                  
   Private                                                   6 (11%)
   Medicaid                                                  43 (74%)
   Uninsured                                                 9 (16%)
                                                             
  Preexisting Conditions *(patients may have more than 1)*   
   SSTI                                                      24 (41%)
   Respiratory Disease                                       22 (38%)
   Gastrointestinal                                          9 (16%)
   Cardiovascular                                            3 (5%)
   Nervous system                                            1 (2%)
   None                                                      19 (33%)
                                                             
  Site of Infection                                          
   Face                                                      4 (7%)
   Lower extremity                                           18 (31%)
   Perineal                                                  21 (36%)
   Trunk                                                     4 (7%)
   Upper extremity                                           11 (19%)

ER: Emergency room, SSTI: Skin and soft tissue infection

The distribution of SSTI sites is shown in Table [2](#T2){ref-type="table"} and reflects an age associated shift. In children ages 0-3 years, 19 (76%) had perineal SSTI which was more common. In contrast, only 2 (11%) of the children ages 4-12 had perineal SSTI and none of the 13-18 year olds. Infections in the extremities were more common in the older youth compared to the youngest children: 3 (12%) in ages 0-3, 13 (68%) in ages 4-12, and 13 (93%) in ages 13-18. Overall, there was a significant association between site of the infection and age group (Fisher\'s Exact p-value \< 0.001) (Table [2](#T2){ref-type="table"}).

###### 

Associations with Age Group

                                                        Age 0-3 N = 25   Age 4-12 N = 19   Age 13-18 N = 14   Fisher\'s Exact Two-tailed P-value
  ----------------------------------------------------- ---------------- ----------------- ------------------ ------------------------------------
  **Site of Infection**                                                                                       \< 0.001
  Face                                                  2 (8%)           1 (5%)            1 (7%)             
  Lower extremity                                       2 (8%)           8 (42%)           8 (57%)            
  Perineal                                              19 (76%)         2 (11%)           0 (0%)             
  Trunk                                                 1 (4%)           3 (16%)           0 (0%)             
  Upper extremity                                       1 (4%)           5 (26%)           5 (36%)            
                                                                                                              
  **Respiratory disease pre-existing condition**        7 (28%)          9 (47%)           6 (43%)            0.42
                                                                                                              
  **SSTI pre-existing condition**                       12 (48%)         9 (47%)           3 (21%)            0.25
                                                                                                              
  **PFT Sub-type 1 (compared to types 2-7 combined)**   19 (79%)         14 (74%)          9 (64%)            0.59

PFT: Pulse field type, SSTI: Skin and soft tissue infection

Nineteen (33%) children had no pre-existing condition. Age group was not associated with having either respiratory disease or SSTI as a pre-existing condition (Fisher\'s Exact p-values \> 0.05 - Table [2](#T2){ref-type="table"}). Pulsed field typing (*Sma*l PFT) of the 58 CAMRSA isolates revealed that they were all USA300 PFT with seven different subtypes (Figure [2](#F2){ref-type="fig"}), and one sub-type dominated in 72% (n = 42) (Table [3](#T3){ref-type="table"}). PFGE sub-type I (compared to sub-types 2-7) was not associated with site of infection or with having respiratory disease or SSTI as a pre-existing condition, all with Fisher\'s Exact p-values \> 0.05 (Table [4](#T4){ref-type="table"}). The DiversiLab typing of the 58 CAMRSA strains revealed that 55 (95%) were indeed USA300 PFT while 3 strains were identified as USA500.

![**USA300 PFT subtypes**. This is a picture of the USA300 strains all run on a single gel and are labeled according to the PFT subtypes in Table 2, 3 & 4.](1471-2431-11-96-2){#F2}

###### 

Molecular epidemiology of USA300 PFT strains (n = 58)

  ----------------------------------------------------------------------------------------------------------------------------
  USA300 PFT subtypes n(%)   Diversilab type\* n(%)   *mec*A         SCC*mec*type   ACME          *lukSF-PV*     *cap*5
  -------------------------- ------------------------ -------------- -------------- ------------- -------------- -------------
  **1 -**42(72%)             USA300-41(98%)\          42             IVa-42         42            42             30(71%)
                             USA500-1(24%)                                                                       

                                                                                                                 

  **2**- 6(10%)              USA300-4(67%)\           6              IVa-6          6             6              6
                             USA500-2(33%)                                                                       

                                                                                                                 

  **3**- 4(7%)               USA300-4                 4              IVa-4          4             4              4

                                                                                                                 

  **4**- 2(3%)               USA300-2                 2              IVa-2          1             2              2

                                                                                                                 

  **5**- 2(3%)               USA300-2                 2              IVa-2          2             2              2

                                                                                                                 

  **6**- 1(2%)               USA300-1                 1              IVa-1          0             1              1

                                                                                                                 

  **7**- 1(2%)               USA300-1                 1              IVa-1          1             1              1

                                                                                                                 

  **Total(n)**               **58**(100%)             **58**(100%)   **58**(100%)   **56**(97%)   **58**(100%)   **46**(79%)
  ----------------------------------------------------------------------------------------------------------------------------

PFT: Pulsed field type; SCC: Staphylococcal Cassette Chromosome, *lukSF-PV*genes that encode Panton-Valentine leukocidin (PVL), ACME: Arginine catabolic mobile element.

\*The DiversiLab strain types are named as corresponding PFT\'s based on a standardized comparison.

For USA300 PFT subtypes please see figure 2.

###### 

Associations with PFT Sub-type

                                                   PFT Sub-type 1 N = 42   PFT Sub-types 2-7 N = 16   Fisher\'s Exact Two-tailed P-value
  ------------------------------------------------ ----------------------- -------------------------- ------------------------------------
  **Site of Infection**                                                                               
  Face                                             2 (5%)                  2 (13%)                    0.35
  Lower extremity                                  11 (26%)                7 (43%)                    
  Perineal                                         16 (38%)                5 (31%)                    
  Trunk                                            4 (10%)                 0 (0%)                     
  Upper extremity                                  9 (21%)                 2 (13%)                    
                                                                                                      
  **Respiratory disease pre-existing condition**   15 (36%)                7 (47%)                    0.54
                                                                                                      
  **SSTI pre-existing condition**                  18 (43%)                6 (40%)                    1.0

PFT: Pulse field type, SSTI: Skin and soft tissue infection

All 58 CAMRSA strains were *mecA and lukSF-PV*positive, with SCC*mec*type IVa; 56 (97%) contained ACME and the *cap5*gene was present in 46 (79%) (Table [3](#T3){ref-type="table"}). We observed that all the *cap5*negative strains belonged to a single USA300 PFT pattern (Table [3](#T3){ref-type="table"} and Figure [2](#F2){ref-type="fig"}).

Discussion
==========

Figure [1](#F1){ref-type="fig"} clearly demonstrates a six fold increase in the incidence of pediatric MRSA infections from 2002 to 2007 (p \< 0.0001). A clear majority of our pediatric MRSA infections were CAMRSA, which is consistent with the trend reported for the United States \[[@B18]\] and Europe \[[@B19],[@B20]\].

A significant association of age with site of infection has for the first time been demonstrated in our study. Perineal MRSA colonization in children has been recorded in the daycare setting \[[@B21]\]. Koski *et al*indicate that pediatric perineal infections with MRSA are increasing \[[@B22]\]. We found that such infections were more common to the 0-3 y-old cohort. This age preference could be due to increased rates of perineal CAMRSA colonization in this age group, but may also reflect use of diapers and possible dermabrasion caused by vigorous wiping of the area during diaper changes or both. Transfer of vancomycin resistance gene *van*A from vancomycin resistant *Enterococcus*to MRSA has been shown to occur in vitro and in vivo \[[@B23]\]. Perineal CAMRSA infection in children could contribute to the emergence of vancomycin resistant *S.aureus*strains when co-colonized with vancomycin resistant *Enterococcus*\[[@B24]\].

Of interest, all of the CAMRSA strains in our study were susceptible to clindamycin, contrary to higher rates of resistance reported for Alaska, Houston and San Francisco \[[@B25]-[@B27]\].

Strain typing of our patients\' MRSA isolates supports the observation that USA300 PFT is the most common causative strain and is clonal \[[@B27]\]. The molecular characteristics of our isolates were similar to the USA300 strains from other published reports in that they were SCC*mec*type IVa and *lukSF-PV*positive \[[@B27],[@B28]\]. 56/58 of the strains were also positive for ACME, a novel mobile genetic region predominantly reported in USA300 MRSA strains that potentially enhance colonization and virulence \[[@B29]\]. We observed that all the 12 strains that were *cap5*gene negative belonged to the predominant USA300 PFT subtype (Table [3](#T3){ref-type="table"} and Figure [2](#F2){ref-type="fig"}). *cap5*gene encodes for a capsule that enhances the virulence of *Staphylococcus aureus*. It has been used as vaccine target. The clinical significance of *cap5*negative strains in our study is unclear at this time.

Typing using the DiversiLab system is rapid and user friendly compared to PFT. However, differentiating PFT USA300 from USA500 is tricky using DiversiLab \[[@B30]\]. Of interest, 3/3 isolates identified by PFT as USA300 were mis-identified by DiversiLab as USA500. These isolates were also positive for ACME which is a mobile genetic element that is thought to be acquired by USA300 as it evolved from its progenitor USA500 \[[@B31]\].

Conclusion
==========

The incidence of CAMRSA infection is increasing in the pediatric population of Northwest Ohio. SSTIs are the most common type of infection and among children \< 3 years of age with perineal SSTIs being the dominant form caused by strain USA300 PFT that carries the SCC*mec*type IVa, *lukSF-PV*gene and ACME. The automated rapid strain typing method, the DiversiLab system, is not as discriminative as PFT.

Further investigations are needed to assess the extent of USA300 perineal colonization in toddlers and to identify unique virulence characteristics to develop strategies for prevention and treatment of these infections.
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###### 

Click here for file

Acknowledgements
================

I would like to thank Jan Tucker of Mercy Integrated Laboratories and Dr. John Schaeufele, President and CEO of Mercy Children\'s Hospital for their support. Nancy Buderer helped with the statistical analysis.
